What Immunome does

Immunome, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington (with intellectual-property and legal offices in Exton, Pennsylvania), publicly traded on NASDAQ under the ticker IMNM. The company develops targeted cancer therapies built on three technology pillars: antibody-drug conjugates (ADCs), radioligand therapies, and small-molecule gamma-secretase inhibitors, with a deliberate focus on novel or underexplored biological targets rather than the HER2/CLDN18.2/HER3 targets that dominate the ADC field. Its lead asset is varegacestat (AL102), an oral once-daily gamma-secretase inhibitor that completed Phase 3 (RINGSIDE) with an 84% reduction in disease-progression risk versus placebo in desmoid tumors; an NDA was submitted in April 2026 and accepted by the FDA in July 2026 (PDUFA April 28, 2027). The pipeline behind varegacestat includes IM-1021, a ROR1-targeted ADC incorporating a proprietary camptothecin-derived HC74 payload now in Phase 1; IM-3050, an FAP-targeted lutetium-177 radioligand that targets a receptor expressed in roughly 75% of solid tumors and entered Phase 1 in mid-2026; IM-1617, an ADC against an undisclosed receptor tyrosine kinase preferentially expressed in colorectal, breast, ovarian, and NSCLC tumors; and two preclinical ADC candidates (IM-1335, IM-1340).

Immunome is pre-commercial — trailing-twelve-month revenue was $4.0 million as of Q1 2026 and the FY2025 net loss was $212.4 million — with all value-creation to date driven by R&D milestones and equity financings rather than product sales. Total disclosed funding exceeds $1.113 billion, most recently via a $400 million public offering priced in December 2025, leaving a cash position of $582.7M–$653.5M that management states is sufficient to fund operations into 2028. The company plans to commercialize varegacestat (if approved) through a rare-disease specialty model: specialty pharmacies, hospital and cancer-center GPO contracts, and a field-based medical science liaison and sales team now being assembled. Customer segments are concentrated in rare oncology (desmoid tumors, ~1,000–1,650 new U.S. cases per year and an estimated $1B addressable opportunity) and broader solid-tumor oncology once the ADC and radioligand programs advance. Five Buy/Overweight initiations from major sell-side firms (H.C. Wainwright, Barclays, Truist, Guggenheim, Evercore ISI) in 2026 reflect analyst confidence in both the near-term varegacestat launch and the longer-duration platform optionality.

Name

Immunome

Legal name

Immunome, Inc.

Website

https://immunome.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

Immunome is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including ADCs, radioligand therapies, and small-molecule inhibitors, with lead asset varegacestat under FDA review for desmoid tumors and a broader solid-tumor pipeline in early-stage trials.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Targeted cancer therapy
• Antibody-drug conjugates
• Radioligand therapy
• Oncology drug development
• Gamma-secretase inhibitor

Headquarters

HQ city

Exton

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue from potential future sales of approved drugs, starting with varegacestat for desmoid tumors. Company is building commercial infrastructure including sales team and medical affairs for anticipated launch. Currently pre-revenue with only $4.0 million TTM revenue reported in 2026.
2. Asset Acquisition Income: Income from acquired antibody assets that enhance targeted cancer therapy portfolio, including 28 antibodies from Atreca acquisition for $5.5 million upfront with potential milestone payments.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Immunome is a clinical-stage oncology company developing a portfolio of targeted cancer therapies, including antibody-drug conjugates (ADCs), radioligand therapies, and small molecule gamma-secretase inhibitors. Lead asset varegacestat (AL102) targets desmoid tumors with NDA accepted by the FDA, while pipeline programs (IM-1021, IM-3050, IM-1617, IM-1340, IM-1335) target various solid tumor antigens including ROR1 and FAP.

Product overview

Immunome is a clinical-stage oncology company developing a portfolio of targeted cancer therapies. The company's pipeline includes near-term opportunities (Varegacestat, a Phase 3 gamma secretase inhibitor for desmoid tumors with NDA submitted to FDA) and mid-term opportunities (IM-1021, a ROR1-targeted ADC in Phase 1, and IM-3050, an FAP-targeted radioligand therapy in Phase 1). Preclinical programs include three ADC candidates (IM-1617, IM-1340, IM-1335) targeting undisclosed solid tumor antigens. The company leverages expertise in antibody-drug conjugates, radioligand therapies, and small molecules, with team members having contributed to development of ADCETRIS, PADCEV, TIVDAK, and TUKYSA.

Differentiator

Problem solved

Functional benefit

Products and services

• Varegacestat (AL102) An investigational once-daily oral gamma-secretase inhibitor (GSI) for the treatment of patients with progressing desmoid tumors. Completed Phase 3 RINGSIDE trial showing 84% reduction in risk of disease progression or death versus placebo; FDA NDA accepted with PDUFA date of April 28, 2027.
• IM-1021 (ROR1 Antibody-Drug Conjugate) A ROR1-targeted ADC optimized for ADC-mediated killing of ROR1 positive tumor cells, incorporating a proprietary camptothecin derivative payload (HC74) with cleavable linker and drug-antibody ratio of 8. In Phase 1 trial for liquid and solid tumors.
• IM-3050 (FAP Radioligand Therapy) An FAP-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cancer-associated fibroblasts in solid tumors. Incorporates small molecule FAP-specific ligand with albumin-binding domain for improved tumor retention. FAP expressed in approximately 75% of solid tumors.
• IM-1617 (Solid Tumor ADC) An ADC targeting an undisclosed receptor tyrosine kinase preferentially expressed in solid tumors including colorectal cancer, breast, ovarian, and non-small cell lung cancer. Mediates immune cell exclusion providing secondary mechanism of action. In Phase 1 trial.
• IM-1340 (Solid Tumor ADC Candidate) An ADC targeting a transport receptor with unique tumor expression profile spanning neuroendocrine tumors and other solid tumors. Demonstrated robust preclinical efficacy with regressions following single dose in tumor models.
• IM-1335 (Solid Tumor ADC Candidate) A potential best-in-class ADC for solid tumors designed to overcome limitations of a prior discontinued ADC against the same target. Shows efficacy in preclinical models with TOP1 payload class toxicity profile in non-human primates.

Quantifiable outcome

• 84% reduction in risk of disease progression or death (HR=0.16, p<0.0001) vs placebo in Phase 3 RINGSIDE trial for desmoid tumors
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Atreca, Inc.coreStrategic or Co-development Partner · 20 May 2024Immunome completed purchase of antibodies and related assets from Atreca, Inc. for $5.5 million upfront with additional milestone payments possible. Acquisition includes 28 antibodies and related materials enhancing Immunome's targeted cancer therapy portfolio. This acquisition was announced December 2023 and closed in May 2024.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Mersana Therapeutics: Clinical-stage ADC developer using proprietary payload platforms (Dolasynthen, Afucosylated antibodies) to target solid tumors. Directly comparable in business model, stage, and therapeutic focus on differentiated ADC payloads.
• Olema Oncology: Clinical-stage oncology biotech developing targeted therapies for women's cancers. Kinney Horn (Immunome's CBO) was previously CBO at Olema, and both companies share similar size, stage, and capital markets profile as small-cap clinical oncology developers.
• MacroGenics: Clinical-stage oncology biotech developing antibody-based therapeutics including ADCs and bispecifics. Bob Lechleider (Immunome's CMO) previously held roles at MacroGenics, and both companies pursue similar solid tumor ADC targets.

Broad incumbents

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with multiple approved products (Illuccix) and a pipeline of radioligand therapies. Comparable in the therapeutic radiopharmaceutical category, though with greater scale and geographic reach.
• Lantheus Holdings: Radiopharmaceutical company with commercial products (Pylarify, Definity) and a pipeline of targeted radioligand therapies. Comparable as a more established player in the same radiopharmaceutical oncology space as Immunome's IM-3050.
• Seagen (acquired by Pfizer): Seagen developed and commercialized ADCETRIS, PADCEV, and TIVDAK, and was acquired by Pfizer for $43B in 2023. Immunome's leadership team and technology platform have direct lineage from Seagen, making it the closest functional and organizational peer.
• ImmunoGen (acquired by AbbVie): ADC-focused biotech acquired by AbbVie for $10.1B in 2024. Developed Elahere (mirvetuximab soravtansine), the first FDA-approved ADC for ovarian cancer. Comparable as a specialist ADC developer with commercialized products in oncology.
• Point Biopharma (acquired by Eli Lilly): Radiopharmaceutical company acquired by Eli Lilly for $1.4B in 2023, developing targeted radioligand therapies for cancer. Directly comparable to Immunome's IM-3050 FAP-targeted radioligand therapy program in technology category.
• Daiichi Sankyo: Japanese pharmaceutical leader with a major ADC franchise (Enhertu, Datroway) developed in partnership with AstraZeneca. Comparable as a major ADC innovator targeting solid tumors with TOP1-payload technology, though at substantially greater scale.

Emerging players

• Molecular Templates: Clinical-stage oncology company developing engineered toxin bodies (ETBs) for cancer treatment. Jack Higgins (Immunome's CSO) previously spent 11 years at Molecular Templates as Chief Development Sciences Officer, providing direct organizational overlap.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Immunome
• LinkedInlinkedin.com/company/immunome-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds22 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunome